Prognostic Role of Systemic Inflammation Response Index in Patients with Non-small Cell Lung Cancer: a Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Nov 12

PMID 39532372

Authors

Xingchen Ye

Menglu Dai

Zhuofang Xiang

Affiliations

Soon will be listed here.

Abstract

Objectives: The significance of the systemic inflammation response index (SIRI) for predicting prognostic outcomes in patients with non-small cell lung cancer (NSCLC) has been analysed in previous studies, but no consistent conclusions have been obtained. Consequently, the present meta-analysis was performed to identify the significance of SIRI in predicting the prognosis of NSCLC.

Design: This study followed the PRISMA guidelines.

Data Sources: PubMed, Web of Science and Embase databases were searched between their inception and 26 November 2023.

Eligibility Criteria For Selecting Studies: Studies investigating the relationship between SIRI and survival outcomes of patients with NSCLC were included.

Data Extraction And Synthesis: The value of SIRI in predicting prognosis in NSCLC cases was predicted using combined hazard ratios (HRs) and 95% CIs.

Results: Nine articles with 3728 cases were enrolled in this study. Based on our combined data, a higher SIRI value was markedly linked with poor overall survival (OS) (HR=2.08, 95% CI 1.68 to 2.58, p<0.001) and inferior progression-free survival (PFS) (HR=1.74, 95% CI 1.47 to 2.07, p<0.001) of NSCLC. According to the subgroup analysis, country, history and cut-off value did not affect the significance of SIRI in predicting OS and PFS in NSCLC (p<0.05).

Conclusions: A higher SIRI value was significantly associated with both OS and PFS in patients with NSCLC. Moreover, SIRI had a stable prognostic efficiency for NSCLC in various subgroups.

References

Jarmuzek P, Kozlowska K, Defort P, Kot M, Zembron-Lacny A . Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023; 15(13). PMC: 10340562. DOI: 10.3390/cancers15133339. View

Vajavaara H, Leivonen S, Jorgensen J, Holte H, Leppa S . Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma. EJHaem. 2022; 3(3):681-687. PMC: 9421995. DOI: 10.1002/jha2.409. View

Hu M, Xu Q, Yang S, Han S, Zhu Y, Lin Q . Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Ann Transl Med. 2020; 8(20):1310. PMC: 7661896. DOI: 10.21037/atm-20-6484. View

Yang H, Wang K, Li B, Li S, Li Y, Yuan L . The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy. Front Oncol. 2021; 11:707041. PMC: 8668866. DOI: 10.3389/fonc.2021.707041. View

Miura N, Mori K, Laukhtina E, Schuettfort V, Abufaraj M, Teoh J . Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Jpn J Clin Oncol. 2021; 51(7):1149-1157. DOI: 10.1093/jjco/hyab023. View

Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion L . CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475(7355):222-5. PMC: 3208506. DOI: 10.1038/nature10138. View

Wu H, Lin C, Tzeng Y, Hung C, Liu S, Yin C . Preoperative systemic inflammation response index: Clinicopathologic predictor of pathological complete response in HER2-positive breast cancer patients receiving neoadjuvant systemic therapy. J Chin Med Assoc. 2023; 87(2):226-235. DOI: 10.1097/JCMA.0000000000001034. View

Jiang S, Wang S, Wang Q, Deng C, Feng Y, Ma F . Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs. Cancer Manag Res. 2021; 13:1315-1322. PMC: 7900776. DOI: 10.2147/CMAR.S287897. View

Shen Y, Qian L, Ding Z, Luo Q, Zhao H, Xia W . Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. Front Oncol. 2021; 11:711206. PMC: 8440980. DOI: 10.3389/fonc.2021.711206. View

10.

Wang H, Shi Y, Shi Y, Cao M, Zhang L, Wu Y . The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer. Int J Clin Pract. 2023; 2023:8893670. PMC: 10212685. DOI: 10.1155/2023/8893670. View

11.

Franklin R, Liao W, Sarkar A, Kim M, Bivona M, Liu K . The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344(6186):921-5. PMC: 4204732. DOI: 10.1126/science.1252510. View

12.

Liang X, Liu B, Yu H, Chen J, Cao Z, Wang S . Prognostic significance of the systemic inflammation response index in gastrointestinal malignancy patients: a pooled analysis of 10,091 participants. Future Oncol. 2023; 19(29):1961-1972. DOI: 10.2217/fon-2023-0545. View

13.

Li S, Yang Z, Du H, Zhang W, Che G, Liu L . Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019; 89(11):E507-E513. DOI: 10.1111/ans.15480. View

14.

Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K . Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. Sci Rep. 2021; 11(1):2741. PMC: 7854616. DOI: 10.1038/s41598-021-82448-1. View

15.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

16.

Wang L, Qin X, Zhang Y, Xue S, Song X . The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: A systematic review and meta-analysis. Front Oncol. 2023; 13:1006233. PMC: 9936064. DOI: 10.3389/fonc.2023.1006233. View

17.

Sawa A, Bando H, Kamohara R, Takeuchi N, Terasaki A, Okazaki M . Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study. Oncology. 2022; 100(11):591-601. DOI: 10.1159/000526963. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Woodard G, Jones K, Jablons D . Lung Cancer Staging and Prognosis. Cancer Treat Res. 2016; 170:47-75. DOI: 10.1007/978-3-319-40389-2_3. View

20.

Zuo R, Zhu F, Zhang C, Ma J, Chen J, Yue P . The response prediction and prognostic values of systemic inflammation response index in patients with advanced lung adenocarcinoma. Thorac Cancer. 2023; 14(16):1500-1511. PMC: 10234781. DOI: 10.1111/1759-7714.14893. View